Researchers to develop new diagnostic test for Chagas disease

November 22, 2012 by James Hataway
A UGA faculty member since 1984, Rick Tarleton is the founding director of the Center for Tropical and Emerging Global Diseases.

(Medical Xpress)—Researchers at the University of Georgia will soon begin a study designed to identify new ways of determining treatment efficacy in Chagas disease, a potentially fatal tropical disease that infects approximately 8 million people worldwide and is the leading parasitic killer in the Americas.

There is currently no easy-to-use and reliable test available to assess if Chagas patients receiving treatment are rid of the parasite that causes the disease, . This project will access the performance of commonly prescribed anti-parasitic drugs and hopefully lead to a new, efficient to detect the parasite.

"The major problem in terms of drug treatment for Chagas disease is that it is virtually impossible to determine if the treatment is effective," said Rick Tarleton, Distinguished Research Professor in the Franklin College of Arts of Sciences department of , and member of UGA's Center for Tropical and Emerging Global Diseases. "The detection of T. cruzi is very difficult because of low parasite numbers and the fact that these are primarily in deep tissues such as the heart."

In the first-ever large-scale study, Tarleton will team up with researchers at the Texas Biomedical Research Institute to study treatment of non-human primates that have become infected with the parasite in their outdoor living environment. The animals will be treated with three versus placebo, and a series of blood tests will search for evidence of infection in the blood.

The results from this project have the potential to significantly improve current treatments, but also to open the doors for new, more advanced drugs.

"There are several existing compounds that are available for use in the treatment of Chagas disease, but they are not frequently used because there is not an acceptable test to tell if they actually worked," Tarleton said. "So the drugs go unused and people die."

Major are also hesitant to invest in drug discovery because they have no way of determining whether their drugs work, or if they are better than existing drugs.

Chagas disease is the leading cause of death among young-to-middle-age adults in endemic areas of South America, and many people live years without symptoms while their hearts and digestive systems suffer irreparable damage.

The T. cruzi parasite is most often spread via a subspecies of blood-feeding insects called triatomines. These insects, commonly known as "kissing bugs" because they tend to bite people on the face and lips, feed and defecate on the skin. Triatomine feces containing the parasite are then rubbed into the bite when humans or animals scratch the wound, rub their eyes or touch their mouths.

Once confined almost exclusively to Latin America, has spread throughout the world. In the United States, the Centers for Disease Control and Prevention estimate 300,000 or more people are infected, and it is becoming increasingly common in domesticated dogs and wild animals.

The current project, made possible by support from The Wellcome Trust of the United Kingdom, will begin within months and run until 2015. Texas Biomed will conduct the experimental protocols with the animals and both Texas Biomed and UGA will conduct biomarker analysis.

Tarleton hopes this project will lead to discoveries that save lives and foster the creation of new treatments for this common and underserved disease.

"Identifying a method to accurately and efficiently determine treatment efficacy will increase utilization of existing therapies and will facilitate the discovery of new therapies," he said.

Explore further: UGA animal vaccine may slow deadly spread of Chagas disease

Related Stories

UGA animal vaccine may slow deadly spread of Chagas disease

February 16, 2012
Chagas disease is the single most common cause of congestive heart failure and sudden death in the world. The devastating parasitic infection affects millions of people throughout Central and South America. But as global ...

FDA approves new test for Chagas disease

November 26, 2011
The Food and Drug Administration has approved Abbott Laboratories' ESA test for Chagas disease, which could be a useful tool in protecting the nation's blood supply from contamination.

300,000 people in U.S. living with Chagas disease: report

July 5, 2012
(HealthDay) -- As many as 300,000 people in the United States may have chronic Chagas disease -- mostly spread by blood-sucking insects -- health officials report.

Recommended for you

Fatty liver can cause damage to other organs via crosstalk

August 21, 2017
Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis ...

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.